Abstract
Vascular smooth muscle cell (SMC) phenotypic modulation plays a key role in atherosclerosis and is classically defined as a switch from a ‘contractile’ phenotype to a ‘synthetic’ phenotype, whereby genes that define the contractile SMC phenotype are suppressed and proliferation and/or migratory mechanisms are induced. There is also evidence that SMCs may take on a ‘proinflammatory’ phenotype, whereby SMCs secrete cytokines and express cell adhesion molecules, e.g. IL-8, IL-6, and VCAM-1, respectively, which may functionally regulate monocyte and macrophage adhesion and other processes during atherosclerosis. Factors that drive the inflammatory phenotype are not limited to cytokines but also include hemodynamic forces imposed on the blood vessel wall and intimate interaction of endothelial cells with SMCs, as well as changes in matrix composition in the vessel wall. However, it is critical to recognize that our understanding of the complex interaction of these multiple signal inputs has only recently begun to shed light on mechanisms that regulate the inflammatory SMC phenotype, primarily through models that attempt to recreate this environment ex vivo. The goal of this review is to summarize our current knowledge in this area and identify some of the key unresolved challenges and questions requiring further study.
References
1.
Gerthoffer WT: Mechanisms of vascular smooth muscle cell migration. Circ Res 2007;100:607–621.
2.
Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767–801.
3.
Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 1994;14:840–856.
4.
Torzewski M, Navarro B, Cheng F, Canisius A, Schmidt T, Bhakdi S, Urban R, Lackner KJ: Investigation of Sudan IV staining areas in aortas of infants and children: possible prelesional stages of atherogenesis. Atherosclerosis 2009;206:159–167.
5.
Hastings NE, Feaver RE, Lee MY, Wamhoff BR, Blackman BR: Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow. Arterioscler Thromb Vasc Biol 2009;29:725–731.
6.
Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715–1722.
7.
Landry DB, Couper LL, Bryant SR, Lindner V: Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997;151:1085–1095.
8.
Steinberg D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002;8:1211–1217.
9.
Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G: Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 2000;902:230–239, discussion 239–240.
10.
Glagov S, Zarins C, Giddens DP, Ku DN: Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med 1988;112:1018–1031.
11.
Malek AM, Alper SL, Izumo S: Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999;282:2035–2042.
12.
Hastings NE, Simmers MB, McDonald OG, Wamhoff BR, Blackman BR: Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol 2007;293:C1824–C1833.
13.
Mitchell GF, Pfeffer MA: Pulsatile hemodynamics in hypertension. Curr Opin Cardiol 1999;14:361–369.
14.
Orr AW, Lee MY, Lemmon JA, Yurdagul A Jr, Gomez MF, Bortz PD, Wamhoff BR: Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2009;29:225–231.
15.
Birukov KG, Bardy N, Lehoux S, Merval R, Shirinsky VP, Tedgui A: Intraluminal pressure is essential for the maintenance of smooth muscle caldesmon and filamin content in aortic organ culture. Arterioscler Thromb Vasc Biol 1998;18:922–927.
16.
Lehoux S, Castier Y, Tedgui A: Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med 2006;259:381–392.
17.
O’Neill LA: Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 2006;5:549–563.
18.
Pietersma A, Tilly BC, Gaestel M, de Jong N, Lee JC, Koster JF, Sluiter W: p38 mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun 1997;230:44–48.
19.
Johnson GL, Nakamura K: The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 2007;1773:1341–1348.
20.
Kavurma MM, Khachigian LM: ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 2003;89:289–300.
21.
Sotoudeh M, Li YS, Yajima N, Chang CC, Tsou TC, Wang Y, Usami S, Ratcliffe A, Chien S, Shyy JY: Induction of apoptosis in vascular smooth muscle cells by mechanical stretch. Am J Physiol Heart Circ Physiol 2002;282:H1709–H1716.
22.
Bayat H, Xu S, Pimentel D, Cohen RA, Jiang B: Activation of thromboxane receptor upregulates interleukin (IL)-1β-induced VCAM-1 expression through JNK signaling. Arterioscler Thromb Vasc Biol 2008;28:127–134.
23.
Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS: Dual regulation of tumor necrosis factor-α-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-ĸB and activator protein-1: modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther 2004;309:978–986.
24.
Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997;272:15817–15824.
25.
Cao S, Zhang X, Edwards JP, Mosser DM: NF-ĸB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006;281:26041–26050.
26.
Autieri MV, Yue TL, Ferstein GZ, Ohlstein E: Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 1995;213:827–836.
27.
Nilsson LM, Nilsson-Ohman J, Zetterqvist AV, Gomez MF: Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys? Curr Opin Lipidol 2008;19:483–490.
28.
Liu Z, Dronadula N, Rao GN: A novel role for nuclear factor of activated T cells in receptor tyrosine kinase and G protein-coupled receptor agonist-induced vascular smooth muscle cell motility. J Biol Chem 2004;279:41218–41226.
29.
Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN: A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. Biochem J 2002;368:183–190.
30.
Liu Z, Zhang C, Dronadula N, Li Q, Rao GN: Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model. J Biol Chem 2005;280:14700–14708.
31.
Nilsson LM, Sun ZW, Nilsson J, Nordstrom I, Chen YW, Molkentin JD, Wide-Swensson D, Hellstrand P, Lydrup ML, Gomez MF: Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2007;292:C1167–C1178.
32.
Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA: The subendothelial extracellular matrix modulates NF-ĸB activation by flow: a potential role in atherosclerosis. J Cell Biol 2005;169:191–202.
33.
Abbott KL, Loss JR 2nd, Robida AM, Murphy TJ: Evidence that Gαq-coupled receptor-induced interleukin-6 mRNA in vascular smooth muscle cells involves the nuclear factor of activated T cells. Mol Pharmacol 2000;58:946–953.
34.
Neeli I, Liu Z, Dronadula N, Ma ZA, Rao GN: An essential role of the Jak-2/STAT-3/cytosolic phospholipase A2 axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. J Biol Chem 2004;279:46122–46128.
35.
Marrero MB, Schieffer B, Li B, Sun J, Harp JB, Ling BN: Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 1997;272:24684–24690.
36.
Seki Y, Kai H, Shibata R, Nagata T, Yasukawa H, Yoshimura A, Imaizumi T: Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 2000;87:12–18.
37.
Sahar S, Dwarakanath RS, Reddy MA, Lanting L, Todorov I, Natarajan R: Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005;96:1064–1071.
38.
Watanabe S, Mu W, Kahn A, Jing N, Li JH, Lan HY, Nakagawa T, Ohashi R, Johnson RJ: Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am J Nephrol 2004;24:387–392.
39.
Miyoshi T, Tian J, Matsumoto AH, Shi W: Differential response of vascular smooth muscle cells to oxidized LDL in mouse strains with different atherosclerosis susceptibility. Atherosclerosis 2006;189:99–105.
40.
Barlic J, Zhang Y, Murphy PM: Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFα-NFĸB-dependent manner. J Biol Chem 2007;282:19167–19176.
41.
Hofnagel O, Luechtenborg B, Stolle K, Lorkowski S, Eschert H, Plenz G, Robenek H: Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004;24:1789–1795.
42.
Daugherty A: Mouse models of atherosclerosis. Am J Med Sci 2002;323:3–10.
43.
Cherepanova OA, Pidkovka NA, Sarmento OF, Yoshida T, Gan Q, Adiguzel E, Bendeck MP, Berliner J, Leitinger N, Owens GK: Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. Circ Res 2009;104:609–618.
44.
Pidkovka NA, Cherepanova OA, Yoshida T, Alexander MR, Deaton RA, Thomas JA, Leitinger N, Owens GK: Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res 2007;101:792–801.
45.
Raines EW, Ferri N: Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005;46:1081–1092.
46.
Doran AC, Meller N, McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:812–819.
47.
Yue TL, Wang X, Sung CP, Olson B, McKenna PJ, Gu JL, Feuerstein GZ: Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res 1994;75:1–7.
48.
Jung YD, Fan F, McConkey DJ, Jean ME, Liu W, Reinmuth N, Stoeltzing O, Ahmad SA, Parikh AA, Mukaida N, Ellis LM: Role of P38 MAPK, AP-1, and NF-ĸB in interleukin-1β-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 2002;18:206–213.
49.
Libby P, Sukhova G, Lee RT, Galis ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25 (suppl 2):S9–S12.
50.
Wang Z, Castresana MR, Newman WH: NF-ĸB is required for TNF-α-directed smooth muscle cell migration. FEBS Lett 2001;508:360–364.
51.
Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ, Roach AG, Westwick J, Williams RJ: Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18:397–403.
52.
Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W, Kreuzer J: Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-ĸB and activator protein-1. Arterioscler Thromb Vasc Biol 2002;22:914–920.
53.
Braun M, Pietsch P, Felix SB, Baumann G: Modulation of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 on human coronary smooth muscle cells by cytokines. J Mol Cell Cardiol 1995;27:2571–2579.
54.
Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J: Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res 1994;74:225–234.
55.
Thorne SA, Abbot SE, Stevens CR, Winyard PG, Mills PG, Blake DR: Modified low density lipoprotein and cytokines mediate monocyte adhesion to smooth muscle cells. Atherosclerosis 1996;127:167–176.
56.
Wright PS, Cooper JR, Kropp KE, Busch SJ: Induction of vascular cell adhesion molecule-1 expression by IL-4 in human aortic smooth muscle cells is not associated with increased nuclear NF-ĸB levels. J Cell Physiol 1999;180:381–389.
57.
Chen L, Frister A, Wang S, Ludwig A, Behr H, Pippig S, Li B, Simm A, Hofmann B, Pilowski C, Koch S, Buerke M, Rose-John S, Werdan K, Loppnow H: Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances interleukin-6 and MCP-1 production. Am J Physiol Heart Circ Physiol 2009;296:H987–H996.
58.
Jiang B, Xu S, Hou X, Pimentel DR, Cohen RA: Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK. J Biol Chem 2004;279:20363–20368.
59.
Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R: Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 2001;65:73–83.
60.
Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-ĸB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–1301.
61.
Braun M, Pietsch P, Zepp A, Schror K, Baumann G, Felix SB: Regulation of tumor necrosis factor alpha- and interleukin-1-beta-induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP. Arterioscler Thromb Vasc Biol 1997;17:2568–2575.
62.
Kawamura A, Baitsch D, Telgmann R, Feuerborn R, Weissen-Plenz G, Hagedorn C, Saku K, Brand-Herrmann SM, von Eckardstein A, Assmann G, Nofer JR: Apolipoprotein E interrupts interleukin-1β signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2007;27:1610–1617.
63.
Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon RO 3rd: Competition for p300 regulates transcription by estrogen receptors and nuclear factor-ĸB in human coronary smooth muscle cells. Circ Res 2000;87:1006–1011.
64.
Nie M, Corbett L, Knox AJ, Pang L: Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and β2-agonists. J Biol Chem 2005;280:2550–2561.
65.
Barnes MJ, Farndale RW: Collagens and atherosclerosis. Exp Gerontol 1999;34:513–525.
66.
Moiseeva EP: Adhesion receptors of vascular smooth muscle cells and their functions. Cardiovasc Res 2001;52:372–386.
67.
Molossi S, Clausell N, Rabinovitch M: Reciprocal induction of tumor necrosis factor-alpha and interleukin-1 beta activity mediates fibronectin synthesis in coronary artery smooth muscle cells. J Cell Physiol 1995;163:19–29.
68.
Qwarnstrom EE, Ostberg CO, Turk GL, Richardson CA, Bomsztyk K: Fibronectin attachment activates the NF-kappa B p50/p65 heterodimer in fibroblasts and smooth muscle cells. J Biol Chem 1994;269:30765–30768.
69.
Yin BL, Hao H, Wang YY, Jiang YJ, Xue S: Downregulating osteopontin reduces angiotensin II-induced inflammatory activation in vascular smooth muscle cells. Inflamm Res 2009;58:67–73.
70.
Kappert K, Blaschke F, Meehan WP, Kawano H, Grill M, Fleck E, Hsueh WA, Law RE, Graf K: Integrins αvβ3 and αvβ5 mediate VSMC migration and are elevated during neointima formation in the rat aorta. Basic Res Cardiol 2001;96:42–49.
71.
Mawatari K, Liu B, Kent KC: Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction. J Vasc Surg 2000;31:375–381.
72.
Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM: NF-ĸB mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol 1998;141:1083–1093.
73.
Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG: α5β1 integrin activates an NF-ĸB-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002;22:5912–5922.
74.
Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ, Pure E: The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001;108:1031–1040.
75.
Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996;87:1069–1078.
76.
Yamamoto M, Yamamoto K, Noumura T: Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. Exp Cell Res 1993;204:121–129.
77.
Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-ĸB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001;50:556–565.
78.
Minami T, Miura M, Aird WC, Kodama T: Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. J Biol Chem 2006;281:20503–20520.
79.
Heino J: The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol 2000;19:319–323.
80.
Chung CH, Lin KT, Chang CH, Peng HC, Huang TF: The integrin α2β1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-ĸB translocation and PDGF production. Br J Pharmacol 2009;156:846–856.
81.
Skinner MP, Raines EW, Ross R: Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol 1994;145:1070–1081.
82.
Hou G, Vogel WF, Bendeck MP: Tyrosine kinase activity of discoidin domain receptor 1 is necessary for smooth muscle cell migration and matrix metalloproteinase expression. Circ Res 2002;90:1147–1149.
83.
Franco C, Hou G, Ahmad PJ, Fu EY, Koh L, Vogel WF, Bendeck MP: Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res 2008;102:1202–1211.
84.
Hahn C, Schwartz MA: Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol 2009;10:53–62.
85.
Dardik A, Yamashita A, Aziz F, Asada H, Sumpio BE: Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-BB and interleukin-1α. J Vasc Surg 2005;41:321–331.
86.
Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, Garcia-Cardena G, Gimbrone MA Jr: Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci USA 2004;101:14871–14876.
87.
Blackman BR, Garcia-Cardena G, Gimbrone MA Jr: A new in vitro model to evaluate differential responses of endothelial cells to simulated arterial shear stress waveforms. J Biomech Eng 2002;124:397–407.
88.
Birukov KG, Shirinsky VP, Stepanova OV, Tkachuk VA, Hahn AW, Resink TJ, Smirnov VN: Stretch affects phenotype and proliferation of vascular smooth muscle cells. Mol Cell Biochem 1995;144:131–139.
89.
Hishikawa K, Oemar BS, Yang Z, Luscher TF: Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res 1997;81:797–803.
90.
Guest TM, Vlastos G, Alameddine FM, Taylor WR: Mechanoregulation of monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Antioxid Redox Signal 2006;8:1461–1471.
91.
Katsumi A, Milanini J, Kiosses WB, del Pozo MA, Kaunas R, Chien S, Hahn KM, Schwartz MA: Effects of cell tension on the small GTPase Rac. J Cell Biol 2002;158:153–164.
92.
Hordijk PL: Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006;98:453–462.
93.
Zampetaki A, Zhang Z, Hu Y, Xu Q: Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-ĸB signaling pathways. Am J Physiol Heart Circ Physiol 2005;288:H2946–H2954.
94.
Chiu JJ, Chen LJ, Chen CN, Lee PL, Lee CI: A model for studying the effect of shear stress on interactions between vascular endothelial cells and smooth muscle cells. J Biomech 2004;37:531–539.
95.
Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008;105:1516–1521.
96.
Pedersen I, David M: MicroRNAs in the immune response. Cytokine 2008;43:391–394.
97.
Urbich C, Kuehbacher A, Dimmeler S: Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581–588.
98.
Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007;179:5082–5089.
99.
O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007;104:1604–1609.
100.
Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, Feldman DS, Schmittgen TD, Elton TS: The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem 2007;282:24262–24269.
101.
Barreau C, Paillard L, Osborne HB: AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2005;33:7138–7150.
102.
Anderson P: Post-transcriptional control of cytokine production. Nat Immunol 2008;9:353–359.
103.
Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U: Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 2007;101:1104–1112.
104.
Ohh M, Smith CA, Carpenito C, Takei F: Regulation of intercellular adhesion molecule-1 gene expression involves multiple mRNA stabilization mechanisms: effects of interferon-gamma and phorbol myristate acetate. Blood 1994;84:2632–2639.
105.
Raineri I, Wegmueller D, Gross B, Certa U, Moroni C: Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic Acids Res 2004;32:1279–1288.
106.
Carballo E, Gilkeson GS, Blackshear PJ: Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (–/–) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFα overproduction. J Clin Invest 1997;100:986–995.
107.
Carballo E, Lai WS, Blackshear PJ: Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 2000;95:1891–1899.
108.
Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT, Sturgill TW: MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 2004;279:10176–10184.
109.
Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P: MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004;23:1313–1324.
110.
Sun L, Stoecklin G, Van Way S, Hinkovska-Galcheva V, Guo RF, Anderson P, Shanley TP: Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem 2007;282:3766–3777.
111.
Croft D, McIntyre P, Wibulswas A, Kramer I: Sustained elevated levels of VCAM-1 in cultured fibroblast-like synoviocytes can be achieved by TNF-alpha in combination with either IL-4 or IL-13 through increased mRNA stability. Am J Pathol 1999;154:1149–1158.
112.
Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 2004;18:1926–1945.
113.
Cully M, Downward J: Translational responses to growth factors and stress. Biochem Soc Trans 2009;37:284–288.
114.
Schreml S, Lehle K, Birnbaum DE, Preuner JG: mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int Immunopharmacol 2007;7:781–790.
115.
Waskiewicz AJ, Flynn A, Proud CG, Cooper JA: Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997;16:1909–1920.
116.
Pyronnet S: Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 2000;60:1237–1243.
117.
Andersson K, Sundler R: Posttranscriptional regulation of TNFα expression via eukaryotic initiation factor 4E (eIF4E) phosphorylation in mouse macrophages. Cytokine 2006;33:52–57.
118.
Wang X, Flynn A, Waskiewicz AJ, Webb BL, Vries RG, Baines IA, Cooper JA, Proud CG: The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 1998;273:9373–9377.
119.
Kjellerup RB, Kragballe K, Iversen L, Johansen C: Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases. Exp Dermatol 2008;17:498–504.
120.
Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, Espel E, Proud CG: The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 2005;23:177–189.
121.
Ishida M, Ishida T, Nakashima H, Miho N, Miyagawa K, Chayama K, Oshima T, Kambe M, Yoshizumi M: Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ Res 2003;93:1218–1224.
122.
Dominguez C, Powers DA, Tamayo N: p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005;8:421–430.
123.
Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R: Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114:1504–1511.
124.
Phillips LC, Klibanov AL, Bowles DK, Ragosta M, Hossack JA, Wamhoff BR: Focused in vivo delivery of plasmid DNA to the porcine vascular wall via intravascular ultrasound destruction of microbubbles. J Vasc Res 2010; in press.
125.
Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR: Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 2007;116:276–284.
126.
Isner JM, Kearney M, Bortman S, Passeri J: Apoptosis in human atherosclerosis and restenosis. Circulation 1995;91:2703–2711.
127.
Swirski FK, Weissleder R, Pittet MJ: Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol, E-pub ahead of print.
128.
Wamhoff BR, Sinha S, Owens GK: Conditional mouse models to study developmental and pathophysiological gene function in muscle; in Feil R, Metzger D (eds): Conditional Mutagenesis: An Approach to Disease Models. Berlin, Springer, 2007, vol 178, pp 441–468.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
